Pricing Log in Create free account

Palisade Bio, Inc. (PALI) vs Pyxis Oncology, Inc. (PYXS)

Palisade Bio, Inc. and Pyxis Oncology, Inc. are both Biotechnology companies. Palisade Bio, Inc. and Pyxis Oncology, Inc. are of similar size ($198.6M and $196.9M). Pyxis Oncology, Inc. has negative trailing earnings, so its P/E is not meaningful; Palisade Bio, Inc. trades at 1.7×. Pyxis Oncology, Inc. has the higher net margin (0.00% vs −4,230.6%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, Palisade Bio, Inc. leads on 8 and Pyxis Oncology, Inc. on 4.

Valuation

Metric PALI PYXS Biotechnology median
P/E 1.74 n/m 10.60
P/S 316.37 n/m 9.40
P/B 1.96 9.29 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 151.22 n/m 9.02
Earnings yield 57.31% (84.94%) (32.88%)
Free cash flow yield (7.62%) (63.94%) (23.13%)

Profitability

Metric PALI PYXS Biotechnology median
Gross margin 95.63% 0.00% 68.51%
Operating margin (4,681.99%) 0.00% 0.00%
Net margin (4,230.60%) 0.00% 0.00%
Free cash flow margin (2,409.27%) 0.00% 0.00%
Return on equity (51.37%) (179.10%) (51.96%)
Return on assets (47.68%) (99.62%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric PALI PYXS Biotechnology median
Revenue growth (TTM) 5,492.59% — 6.76%
EPS growth (last fiscal year) 97.06% 3.03% 29.88%
Revenue growth, 5-year CAGR 72.86% — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric PALI PYXS Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 24.26 1.34 4.97
Net debt to EBITDA 7.37 0.82 1.01

Dividend

Metric PALI PYXS Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric PALI PYXS Biotechnology median
Market cap 196.93m 198.55m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack